Drugs for the Prevention and Treatment of Cardiac Allograft Vasculopathy
Shuchita Gupta MD*
Thomas Jefferson University Hospital, Philadelphia, PA, USA
- *Corresponding Author:
- Shuchita Gupta MD
Jefferson Heart Institute, Thomas Jefferson University
925 Chestnut Street, Suite 323A, Philadelphia, PA19107,USA
E-mail: [email protected]
Received date: September 29, 2014; Accepted date: October 28, 2014; Published date: October 31, 2014
Citation: Shuchita Gupta MD (2014) Drugs for the Prevention and Treatment of Cardiac Allograft Vasculopathy. Cardiol Pharmacol 3:123. doi: 10.4172/2329-6607.1000123
Copyright: © 2014 Shuchita Gupta MD. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cardiac allograft vasculopathy (CAV) of heart transplants is responsible for up to one-third of deaths at 5 years following cardiac transplantation. Risk factors for CAV include both traditional risk factors and immune factors. Drugs used for prevention and treatment of CAV include statins, calcium channel blockers and immunosuppressive agents. This review discusses the currently available drugs for CAV, the evidence behind their use, and future targets of therapy.